Sugi Predict

Sugi Predict / Targets / HDAC9

HDAC9

Histone deacetylase 9 · Q9UKV0 · HDAC9 on Sugi Atlas →

345,354 patent compounds predicted against HDAC9, 225,305 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL28250 SCHEMBL28250 0.57 14/20
SCHEMBL29476 SCHEMBL29476 0.57 14/20
SCHEMBL31064 SCHEMBL31064 0.57 14/20
SCHEMBL30259 SCHEMBL30259 0.57 14/20
SCHEMBL28328 SCHEMBL28328 0.61 13/20
SCHEMBL28329 SCHEMBL28329 0.61 13/20
SCHEMBL28330 SCHEMBL28330 0.61 13/20
SCHEMBL29695 SCHEMBL29695 0.61 13/20
SCHEMBL30199 SCHEMBL30199 0.61 13/20
Vorinostat Vorinostat (SCHEMBL9018) 1.00 12/20
Iodipamide Iodipamide (SCHEMBL37678) 0.41 12/20
Trichostatin Trichostatin (SCHEMBL19886) 1.00 10/20
SCHEMBL34229 SCHEMBL34229 0.51 10/20
SCHEMBL19539 SCHEMBL19539 0.48 10/20
SCHEMBL28840 SCHEMBL28840 0.61 9/20
SCHEMBL28841 SCHEMBL28841 0.61 9/20
SCHEMBL28842 SCHEMBL28842 0.61 9/20
SCHEMBL29955 SCHEMBL29955 0.61 9/20
SCHEMBL29956 SCHEMBL29956 0.61 9/20
SCHEMBL21138 SCHEMBL21138 0.49 9/20

Clinical trials — most relevant to HDAC9 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients PHASE3UNKNOWN
SB939 in Treating Patients With Recurrent or Metastatic Prostate Cancer PHASE2COMPLETED
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS PHASE2COMPLETED
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma PHASE1/PHASE2COMPLETED
An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab PHASE1/PHASE2RECRUITING
Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft TIssue Sarcoma After Pre-treatment Failure PHASE2COMPLETED
LBH589 Treatment for Refractory Clear Cell Renal Carcinoma PHASE2COMPLETED
Chidamide Combined With Toripalimab in Sarcoma PHASE2COMPLETED
IST Neoadjuvant Abraxane in Newly Diagnosed Breast Cancer PHASE2UNKNOWN
Voronistat in Pediatric Patients With Drug Resistant Epilepsy PHASE2UNKNOWN
An Exploratory Study of Pembrolizumab Plus Entinostat in Non-Inflamed Stage III/IV Melanoma PHASE2COMPLETED
Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes PHASE1/PHASE2COMPLETED
Sintilimab Combined With Chidamide in Treating Peripheral T Cell Lymphoma PHASE2RECRUITING
Safety Study of Bevacizumab, Everolimus and LBH589 (BEL) for Advanced Solid Tumors PHASE1COMPLETED
Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma PHASE1UNKNOWN
Safety Study of the Histone Deacetylase Inhibitor, CHR-3996, in Patients With Advanced Solid Tumours PHASE1COMPLETED
Panobinostat and Epirubicin in Treating Patients With Metastatic Malignant Solid Tumors PHASE1COMPLETED
Pracinostat and Gemtuzumab Ozogamicin (PraGO) in Patients With Relapsed/Refractory Acute Myeloid Leukemia PHASE1COMPLETED
SB939 in Treating Patients With Locally Advanced or Metastatic Solid Tumors PHASE1COMPLETED
Belinostat for Solid Tumors and Lymphomas in Patients With Varying Degrees of Hepatic Dysfunction PHASE1COMPLETED
A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers PHASE1COMPLETED
AR-42 and Decitabine in Treating Patients With Acute Myeloid Leukemia PHASE1COMPLETED
ERB-B4 After Treatment With HDAC Inhibitor in ER+ Tamoxifen Refractory Breast Cancer EARLY_PHASE1WITHDRAWN
Epigenetic Evaluation of HAT/HDAC Activity in PBMC From Patients With Clinically Isolated Syndrome nanUNKNOWN
Chi-GVM Regimen for the Treatment of R/R PTCL nanUNKNOWN
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma nanUNKNOWN
Effect of Exercise Gene Expression and Histone Modifications in Patients With Hemiplegia nanRECRUITING
Vorinostat Before Surgery in Treating Patients With Triple-Negative Breast Cancer nanWITHDRAWN
Profiling and Targeting Epigenetic Marks to Improve Diagnosis and Therapeutic Approaches in Head and Neck Cancer nanRECRUITING
Imaging Histone Deacetylase in the Heart nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a HDAC9 binder may also engage these)

ProteinNameSimilarity
P83038 — 1.000 P83038 →
Q99P99 — 1.000 Q99P99 →
HDAC5 Histone deacetylase 5 1.000 landscape →
Q5R902 — 1.000 Q5R902 →
Q80ZH1 — 0.998 Q80ZH1 →
Q9Z2V6 — 0.997 Q9Z2V6 →
HDAC4 Histone deacetylase 4 0.996 landscape →
P23899 — 0.993 P23899 →
Q9H334 — 0.993 Q9H334 →
Q58NQ4 — 0.993 Q58NQ4 →
Q6NZM9 — 0.992 Q6NZM9 →
O17323 — 0.991 O17323 →
NR4A3 Nuclear receptor subfamily 4 group A member 3 0.991 landscape →
Q03365 — 0.991 Q03365 →
P27889 — 0.991 P27889 →
MAP3K13 Mitogen-activated protein kinase kinase kinase 13 0.991 landscape →
Q9WVB2 — 0.991 Q9WVB2 →
Q5RER5 — 0.991 Q5RER5 →
P35680 — 0.991 P35680 →
P0CF24 — 0.991 P0CF24 →
Q62431 — 0.991 Q62431 →
Q812B1 — 0.991 Q812B1 →
Q9H329 — 0.991 Q9H329 →
Q6NSM8 — 0.990 Q6NSM8 →
Q5QL03 — 0.990 Q5QL03 →
P24610 — 0.990 P24610 →
P62515 — 0.990 P62515 →
Q92539 — 0.990 Q92539 →
Q80TZ9 — 0.990 Q80TZ9 →
Q6P4S6 — 0.990 Q6P4S6 →